âGrady is a global-minded optical industry executive with experience in the C-Suite, as a board member and as a consultant for several world-class organizations. He is the ideal leader for the team as they finalize development and business planning, âsaid OcuDoc Board member and optical industry pioneer E. dean butler. Prior to founding his own consulting firm, Mr. Lenski served as the Americas Marketing Director (CMO) for Hoya Vision Care, and prior to joining Hoya he worked at Performance Optics / Vision Ease as CMO and vice-president of sales in North America. He held a long tenure at PPG, finally occupying the position of General Manager of Adequacities for Transitions.Â® Optical. During his tenure he launched and managed companies in North America and Asia Pacific in addition to leading global business development and strategy.
âI am delighted to join the OcuDoc team at this exciting stage in its development. This technology will be a game-changer and serve so many eyecare professionals around the world: eyecare professionals, retailers and most importantly their patients and clients, âsaid Lenski. The OcuDoc team is targeting delivery of its prototype device for specific market testing in the second quarter of next year.
OcuDoc Mobile aims to be the first and only standalone smartphone app capable of providing accurate, fast and objective auto-refraction and telerefraction.â¢, all without the need for additional equipment. In United States and other regulated markets, ECPs and retailers will be able to use OcuDoc Mobile as an everyday autorefractor and send the app for patient and home caregiver use, with the results sent back to the PCE. In less regulated markets around the world, OcuDoc Mobile will help uplift the emerging middle class globally by providing an objective, accessible and inexpensive solution for vision screening and diagnosis to the billions of people without access. to effective care.
OcuDoc is an eye medical diagnostic software company whose major software applications test and monitor vision, enabling both in-person telemedicine and telemedicine; all based on an exclusive and patented technology developed at The Ohio State University. Learn more about https://www.ocudocmobile.com.
This press release may contain information that may be considered as forward-looking statements. These forward-looking statements are not guarantees of the future performance of the product or the company. The statements contained in this press release have not been evaluated by the FDA, and OcuDoc Mobile is currently not available for purchase or use in United States.
SOURCE OcuDoc, Inc